Wall Street Analysts Think CorMedix (CRMD) Could Surge 32.04%: Read This Before Placing a Bet

Group 1 - CorMedix (CRMD) shares have increased by 21.4% over the past four weeks, closing at $14.64, with a mean price target of $19.33 indicating a potential upside of 32% [1] - The average price targets from analysts range from a low of $17.00 to a high of $21.00, with a standard deviation of $1.37, suggesting a relatively high agreement among analysts [2] - Analysts are optimistic about CRMD's earnings prospects, as indicated by a 53.6% increase in the Zacks Consensus Estimate for the current year over the past month [10][11] Group 2 - The Zacks Rank for CRMD is 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [11] - There is a strong correlation between trends in earnings estimate revisions and near-term stock price movements, supporting the expectation of an upside in CRMD [9]